PFE vs LLY
Pfizer · Eli Lilly
| PFE Pfizer Healthcare | LLY Eli Lilly Healthcare | |
|---|---|---|
| Market | ||
| Price | $30.52 +1.90% | $1,417.54 +3.19% |
| Market cap | $174.0B | $1.33T |
| P/E (TTM) | 40.1 | 48.4 |
| Dividend yield | 5.38% | 0.75% |
| 52-week range | $23.62 – $30.67 | $809.63 – $1,408.38 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 | Eli Lilly (LLY): Two Drugs Drove 88% Of Growth, EPS Hit By $4.57 R&D Oct 31, 2026 |
| Latest earnings | ||
| Reported | — | Oct 29, 2026 |
| Revenue | — | $24.4 billion +39% YoY |
| EPS | — | $7.22 +7% YoY |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +39% +48% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Shared topics: GLP-1 Mergers & Acquisitions
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.